Opendata, web and dolomites

Trep-AB SIGNED

Repurposing clinically approved antibacterial drugs for treponematoses therapy

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Trep-AB project word cloud

Explore the words cloud of the Trep-AB project. It provides you a very rough idea of what is the project "Trep-AB" about.

lactams    macrolide    antibacterial    advantage    patients    recurrent    microorganism    mutations    treponemal    candidate    clarify    tremendous    pallidum    eradication    broadly    culture    survive    treatment    oral    grown    standard    lesion    antibiotics    current    basis    allergy    cure    human    global    unknown    expertise    penetration    strains    efficacy    yaws    rabbits    campaign    events    reduce    resource    trials    team    susceptibility    investigational    preliminary    stages    incorporate    speaking    penicillin    treponematoses    syphilis    central    similarity    regimens    efficacious    confirmed    options    treponema    drug    conducting    shortage    jeopardize    prediction    candidates    antibiotic    prioritized    resistant    resistance    azithromycin    restricted    infection    therapeutic    computational    experimentally    spirochetes    shows    risk    good    disseminate    biological    infected    acquire    cns    validated    bacteria    injectable    combination    clinical    drugs    profile    randomized    burden    nervous    confer   

Project "Trep-AB" data sheet

The following table provides information about the project.

Coordinator
FUNDACION PRIVADA DE LUCHA CONTRA EL SIDA 

Organization address
address: CARRETERA DE CANYET HOSPITAL GERMANS TRIAS I PUJOL PLANTA 2
city: BADALONA
postcode: 8916
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 1˙498˙790 €
 EC max contribution 1˙498˙790 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2019-STG
 Funding Scheme ERC-STG
 Starting year 2020
 Duration (year-month-day) from 2020-02-01   to  2025-01-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    FUNDACION PRIVADA DE LUCHA CONTRA EL SIDA ES (BADALONA) coordinator 1˙150˙678.00
2    UNIVERSITY OF WASHINGTON US (SEATTLE WA) participant 348˙111.00

Map

 Project objective

Current therapeutic options for human treponematoses, syphilis and yaws, are, broadly speaking, restricted to one antibiotic: injectable penicillin. The drug susceptibility profile of Treponema pallidum (T.p) is unknown because the microorganism could not be grown in culture. Treatment failure after penicillin has been related to syphilis bacteria that survive in the central nervous system (CNS) and the potential of strains to acquire resistance to penicillin has recently been recognized. Yaws can be treated with azithromycin but there is a real risk that macrolide-resistant strains disseminate widely and jeopardize the global eradication campaign. I propose a research program to have other validated treatment options with good CNS penetration that are efficacious for all the stages of treponemal infection. Our preliminary results using computational prediction of drug activity based on similarity to drugs with known activity against T.p. and other spirochetes shows several candidate antibiotics. I will take advantage of recent developments in culture methods for determination of drug susceptibility to test 20 prioritized drugs. These results will be confirmed in experimentally infected rabbits treated with the investigational drugs and assessed for lesion development and T.p. burden. My second approach will exploit the established expertise of my team conducting randomized clinical trials to evaluate the efficacy of the 2 most promising candidates compared to standard treatment to cure patients with syphilis/yaws. Such studies will incorporate in-depth studies of recurrent events among study participants, to further clarify the biological basis and identify mutations that confer resistance to B-lactams. New antibacterial oral drugs for the treatment of treponematoses will be a tremendous resource in case of penicillin treatment-failure, resistance, shortage, allergy, or for use in yaws combination regimens to reduce the likelihood of resistance selection.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TREP-AB" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TREP-AB" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

CohoSing (2019)

Cohomology and Singularities

Read More  

CHIPTRANSFORM (2018)

On-chip optical communication with transformation optics

Read More  

CoolNanoDrop (2019)

Self-Emulsification Route to NanoEmulsions by Cooling of Industrially Relevant Compounds

Read More